This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Plegridy
  • /
  • Study to Evaluate the Efficacy and Safety of Dimet...
Clinical trial

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Read time: 3 mins
Last updated:12th Mar 2019
Identifier: NCT03870763

The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS. The other objectives of this study are to evaluate the safety and tolerability of dimethyl fumarate and peginterferon beta-1a and to assess the effect of dimethyl fumarate and peginterferon beta-1a, both compared with placebo, on additional clinical and radiological measures of disease activity.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 340 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis
Estimated Study Start Date: March 12, 2019
Estimated Primary Completion Date: February 28, 2020
Estimated Study Completion Date: February 28, 2020

Arms:
- Experimental:
Dimethyl Fumarate 240 mg
- Experimental: Peginterferon Beta-1a 125 µg
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2019-03-12
Study type(s) Interventional
Expected enrolment 340
Study start date 2019-03-12
Estimated primary completion date 2020-02-28

View full details